Value of usefulness of diffuse optical spectroscopic imaging for monitoring efficacy of aingle agent bevacizumab followed by Paclitaxel in breast cancer patients

Not Applicable

Recruiting

• Conditions: Stage3/4 breast cancer patients

• Registration Number: JPRN-UMIN000015837
• Lead Sponsor: International Medical Center, Saitama Medical University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-12-03
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

(1) Patients who did not get informed consents on paper (2) Patient whom doctor judges this treatment is suirtable for.

Study & Design

• Study Type: Interventional,observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The early hemoglobin response to single-agent bevacizumab.